Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer.
Ranson, Malcolm R Cheeseman, Sue White, Shane C Margison, Jennifer M
Ranson, Malcolm R
Cheeseman, Sue
White, Shane C
Margison, Jennifer M
Citations
Altmetric:
Abstract
Anthracyclines are amongst the most active drugs in the treatment of breast cancer. Stealth liposomal doxorubicin (Caelyx, Doxil, Alza Pharmaceuticals Inc.) is a promising new agent under investigation for the treatment of breast cancer and other solid tumours. The liposomal encapsulation alters drug pharmacokinetics and leads to a marked change in toxicity profile compared to non-liposomal doxorubicin. The results of recently completed and ongoing clinical trials in breast cancer are reviewed.
Description
Date
2001-02
Publisher
Collections
Keywords
Breast Cancer
Type
Article
Citation
Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer. 2001, 37 (2):115-20 Crit. Rev. Oncol. Hematol.